celecoxib has been researched along with aromasil in 21 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 10 (47.62) | 29.6817 |
| 2010's | 10 (47.62) | 24.3611 |
| 2020's | 1 (4.76) | 2.80 |
| Authors | Studies |
|---|---|
| Bilter, GK; Dias, J; Huang, Z; Keon, BH; Lamerdin, J; MacDonald, ML; Michnick, SW; Minami, T; Owens, S; Shang, Z; Westwick, JK; Yu, H | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Chow, LW; Toi, M; Wong, JL | 1 |
| Ellis, MJ | 1 |
| Chow, LW; Guan, XY; Loo, WT; Toi, M; Zhu, L | 1 |
| Cheng, CW; Chow, LW; Toi, M; Wong, JL | 1 |
| Canney, PA; Curto, J; Machin, MA | 1 |
| Abbattista, A; Bapsy, P; Carpentieri, M; Dirix, LY; Falcon, S; Gomez, H; Ignacio, J; Jones, S; Lobelle, JP; Nag, S; Paridaens, R; Raghunadharao, D | 1 |
| Chow, LW; Lam, CK; Loo, WT; Toi, M; Yip, AY | 1 |
| Boneberg, EM; Fürstenberger, G; Legler, DF; Senn, HJ | 1 |
| Bachelot, T; Crétin, J; Debled, M; Delozier, T; Falandry, C; Freyer, G; Mauriac, L; Mille, D; Pujade-Lauraine, E; Romestaing, P; You, B | 1 |
| Glück, S | 1 |
| Baildam, A; Barr, L; Bundred, NJ; Cheung, KL; Cramer, A; Dixon, JM; Flint, P; Grassby, S; Johnson, R; Landberg, G; Morris, J; Renshaw, L; Turner, L; Young, O | 1 |
| Chow, LW; Chu, WP; Loo, WT; Toi, M; Yip, AY | 1 |
| Brueggemeier, RW; Layman, RM; Lehman, AM; Lustberg, MB; Mrozek, E; Povoski, SP; Ramaswamy, B; Ruppert, AS; Shapiro, CL; Shiels, DR; Sugimoto, Y; Zhao, W; Ziegler, RM | 1 |
| Chan, MS; Chanplakorn, N; Chanplakorn, P; Chow, LW; Ono, K; Sasano, H; Suzuki, T; Wang, L; Wing, L; Yiu, CC | 1 |
| Allevi, G; Andreis, D; Bottini, A; Buffa, FM; Byrne, D; Cummings, M; Deb, S; Ferrero, G; Fox, SB; Generali, D; Harris, AL; Lakhani, SR; Martinotti, M; Reid, LE; Taylor, M | 1 |
| Ch Yiannakopoulou, E | 1 |
| Aristarco, V; Bonanni, B; Caldarella, P; DeCensi, A; Feroce, I; Gandini, S; Guerrieri-Gonzaga, A; Johansson, H; Lazzeroni, M; Macis, D; Pagani, G; Pruneri, G; Serrano, D; Toesca, A | 1 |
| Aristarco, V; Bonanni, B; DeCensi, A; Gandini, S; Gjerde, J; Guerrieri-Gonzaga, A; Johansson, H; Lazzeroni, M; Macis, D; Mellgren, G; Rajasekaran, A; Serrano, D; Williard, CV | 1 |
3 review(s) available for celecoxib and aromasil
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Exemestane as first-line therapy in postmenopausal women with recurrent or metastatic breast cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Celecoxib; Estrogens; Female; Humans; Letrozole; Middle Aged; Multicenter Studies as Topic; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Pyrazoles; Randomized Controlled Trials as Topic; Recurrence; Salvage Therapy; Sulfonamides; Tamoxifen; Triazoles | 2010 |
Interaction of Salicylates and the Other Nonsteroidal Anti-Inflammatory Agents With Breast Cancer Endocrine Treatment: Systematic Review.
Topics: Androstadienes; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Aspirin; Breast Neoplasms; Celecoxib; Drug Synergism; Female; Humans; Salicylates; Tamoxifen | 2015 |
14 trial(s) available for celecoxib and aromasil
| Article | Year |
|---|---|
Celecoxib anti-aromatase neoadjuvant (CAAN) trial for locally advanced breast cancer: preliminary report.
Topics: Androstadienes; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Carcinoembryonic Antigen; Celecoxib; Enzyme Inhibitors; Female; Humans; Letrozole; Middle Aged; Neoadjuvant Therapy; Nitriles; Postmenopause; Pyrazoles; Sulfonamides; Treatment Outcome; Triazoles | 2003 |
Her2/neu expression predicts the response to antiaromatase neoadjuvant therapy in primary breast cancer: subgroup analysis from celecoxib antiaromatase neoadjuvant trial.
Topics: Aged; Aged, 80 and over; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Celecoxib; Cyclooxygenase Inhibitors; Female; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Letrozole; Middle Aged; Neoadjuvant Therapy; Nitriles; Prognosis; Pyrazoles; Receptor, ErbB-2; Sulfonamides; Treatment Outcome; Triazoles | 2004 |
Serum lipid profiles in patients receiving endocrine treatment for breast cancer--the results from the Celecoxib Anti-Aromatase Neoadjuvant (CAAN) Trial.
Topics: Aged; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Celecoxib; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cyclooxygenase 2 Inhibitors; Enzyme Inhibitors; Female; Humans; Lipids; Middle Aged; Pyrazoles; Sulfonamides; Triglycerides | 2005 |
A feasibility study of the efficacy and tolerability of the combination of Exemestane with the COX-2 inhibitor Celecoxib in post-menopausal patients with advanced breast cancer.
Topics: Adult; Aged; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Celecoxib; Cyclooxygenase 2 Inhibitors; Disease-Free Survival; Feasibility Studies; Female; Humans; Middle Aged; Postmenopause; Pyrazoles; Quality of Life; Sulfonamides; Treatment Outcome | 2006 |
Treatment of advanced hormone-sensitive breast cancer in postmenopausal women with exemestane alone or in combination with celecoxib.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Celecoxib; Disease Progression; Female; Humans; Middle Aged; Neoplasms, Hormone-Dependent; Postmenopause; Pyrazoles; Sulfonamides; Tissue Distribution; Treatment Outcome | 2008 |
Celecoxib anti-aromatase neoadjuvant (CAAN) trial for locally advanced breast cancer.
Topics: Aged; Aged, 80 and over; Androstadienes; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Celecoxib; Cholesterol; Cyclooxygenase 2 Inhibitors; Female; Humans; Lipids; Middle Aged; Neoadjuvant Therapy; Postmenopause; Pyrazoles; Sulfonamides; Treatment Outcome; Tumor Burden | 2008 |
Celecoxib and exemestane versus placebo and exemestane in postmenopausal metastatic breast cancer patients: a double-blind phase III GINECO study.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Anti-Inflammatory Agents, Non-Steroidal; Aromatase Inhibitors; Breast Neoplasms; Cardiovascular Diseases; Celecoxib; Chemotherapy, Adjuvant; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Liver Neoplasms; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Neoplasms, Hormone-Dependent; Placebos; Postmenopause; Prognosis; Pyrazoles; Soft Tissue Neoplasms; Sulfonamides; Survival Rate; Treatment Outcome | 2009 |
Cyclooxygenase-2 inhibition does not improve the reduction in ductal carcinoma in situ proliferation with aromatase inhibitor therapy: results of the ERISAC randomized placebo-controlled trial.
Topics: Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Aromatase Inhibitors; Breast Neoplasms; Carcinoma in Situ; Carcinoma, Ductal, Breast; Celecoxib; Cell Proliferation; Cyclooxygenase 2; Female; Humans; Immunohistochemistry; Ki-67 Antigen; Placebos; Pyrazoles; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Sulfonamides | 2010 |
Bone metabolism and quality-of-life of postmenopausal women with invasive breast cancer receiving neoadjuvant hormonal therapy: sub-analyses from celecoxib anti-aromatase neoadjuvant (CAAN) trial.
Topics: Androstadienes; Animals; Antineoplastic Agents; Aromatase Inhibitors; Biomarkers; Bone and Bones; Bone Density; Breast Neoplasms; Celecoxib; Cyclooxygenase 2 Inhibitors; Drug Therapy, Combination; Female; Humans; Neoadjuvant Therapy; Postmenopause; Pyrazoles; Quality of Life; Sulfonamides; Surveys and Questionnaires; Treatment Outcome | 2011 |
Phase II trial of neoadjuvant exemestane in combination with celecoxib in postmenopausal women who have breast cancer.
Topics: Aged; Aged, 80 and over; Androstadienes; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Lobular; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Immunoenzyme Techniques; Lymphatic Metastasis; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Postmenopause; Pyrazoles; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Sulfonamides; Survival Rate; Treatment Outcome | 2011 |
Increased 5α-reductase type 2 expression in human breast carcinoma following aromatase inhibitor therapy: the correlation with decreased tumor cell proliferation.
Topics: 17-Hydroxysteroid Dehydrogenases; 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Ductal, Breast; Celecoxib; Cell Proliferation; Female; Humans; Immunohistochemistry; Letrozole; Neoadjuvant Therapy; Nitriles; Pyrazoles; Receptors, Androgen; Sulfonamides; Treatment Outcome; Triazoles | 2011 |
COX-2 expression is predictive for early relapse and aromatase inhibitor resistance in patients with ductal carcinoma in situ of the breast, and is a target for treatment.
Topics: Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating; Celecoxib; Cohort Studies; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Prognosis; Pyrazoles; Sulfonamides; Survival Analysis | 2014 |
A Randomized, Placebo-Controlled, Phase II, Presurgical Biomarker Trial of Celecoxib Versus Exemestane in Postmenopausal Breast Cancer Patients.
Topics: Aged; Androstadienes; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Celecoxib; Cell Proliferation; Female; Humans; Immunohistochemistry; Ki-67 Antigen; Middle Aged; Postmenopause | 2016 |
Prognostic impact of genetic variants of CYP19A1 and UGT2B17 in a randomized trial for endocrine-responsive postmenopausal breast cancer.
Topics: Aged; Androstadienes; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Aromatase; Breast Neoplasms; Celecoxib; Female; Genetic Variation; Glucuronosyltransferase; Humans; Middle Aged; Minor Histocompatibility Antigens; Polymorphism, Single Nucleotide; Postmenopause; Prognosis | 2020 |
4 other study(ies) available for celecoxib and aromasil
| Article | Year |
|---|---|
Identifying off-target effects and hidden phenotypes of drugs in human cells.
Topics: Bacterial Proteins; Cell Line; Cell Proliferation; Cluster Analysis; Drug Design; Drug Evaluation, Preclinical; Genetics; Humans; Luminescent Proteins; Molecular Structure; Phenotype; Recombinant Fusion Proteins; Signal Transduction; Structure-Activity Relationship | 2006 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Neoadjuvant endocrine therapy as a drug development strategy.
Topics: Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biomarkers; Celecoxib; Clinical Trials as Topic; Drug Design; Humans; Ki-67 Antigen; Neoadjuvant Therapy; Neoplasms, Hormone-Dependent; Pyrazoles; Signal Transduction; Sulfonamides; Tamoxifen | 2004 |
Reduced expression of cyclooxygenase-2 in primary breast cancer.
Topics: Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Celecoxib; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Down-Regulation; Drug Therapy, Combination; Female; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Pyrazoles; Reverse Transcriptase Polymerase Chain Reaction; Sulfonamides; Treatment Failure | 2008 |